Cyclogest® (Progesterone Suppository)
- Indication
- Luteal phase support for in vitro fertilization (IVF) and assisted reproduction; maintenance of early pregnancy
- Manufacturer
- Actavis/Teva (registered in UK and Hong Kong)
- Lecheng Status
- First use in mainland China completed (April 2026)
- Available At
- 木棉花生殖与遗传医院（海南）
- Regulatory Status
- FDA: Not approved; EMA: Approved (UK registration); NMPA: Not yet approved in mainland China
Common Questions
Who is eligible for this treatment?
Patients with confirmed indication and a treating physician referral. International patients need a medical visa (M visa).
How can I access this treatment in Lecheng?
Contact the hospital listed in the quick facts section. International patients can use medical agents or contact the hospital directly.
What is the cost of treatment?
Costs vary by treatment protocol and length of stay. Please contact the hospital for accurate pricing. International insurance may be accepted.
Indication: Luteal phase support for in vitro fertilization (IVF) and assisted reproduction; maintenance of early pregnancy
Manufacturer: Actavis/Teva (registered in UK and Hong Kong)
The world's only progesterone formulation that can be administered rectally for luteal support. Provides a unique alternative to oral, intramuscular, and vaginal gel formulations with improved comfort and compliance. Fills a clinical gap in mainland China's assisted reproduction field.
Sources & Citations
- hainanlecheng.com · accessed 2026-07-03